Factors Affecting the Success of Multi Drug Resistance (MDR-TB) Tuberculosis Treatment in Residential Surakarta
Abstract
Background: Tuberculosis (TB) is a global public health concern. The new challenge in TB control is the development of TB multi drug resistance (MDR-TB). Indonesia ranks 8th highest in the incidence of MDR-TB with 8,900 MDR-TB cases in 2004. A case was defined as MDR-TB if the Mycobacterium tuberculosis was resistant to rifampicin dan isoniazid. This study aimed to determine the factors affecting the success of multi drug resistance (MDR-TB) tuberculosis treatment.
Subjects and Method: This was an analytic observational study using case control design. The study was conducted at Dr. Moewardi Hospital, Surakarta, Central Java, Indonesia, in October 2014. The case population were MDR-TB patients visiting Dr. Moewardi Hospital for TB treatment from 2011 to October 2014. A sample of 84 TB cases consisting of 26 patients who dropped out, defaulted, or died, and 58 patients who successfully completed TB treatment, were selected for this study. The independent variables were sex, age, marital status, nutrional status, education, employment status, drug side effect, family support, and distance to health facility. The dependent variable was success of treatment. The data were collected by direct interview, questionnaire, and medical record. Logistic regression was employed for data analysis.
Results: Age (OR= 0.93; 95% CI = 0.88 to 0.97; p=0.004) and drug side effect (OR= 6.84; 95% CI = 2.50 to 18.74; p<0.001) affected the success of TB treatment and statistically significant. Sex (OR= 0.66; 95% CI = 0.17 to 2.58; p=0.556), education (OR=0.90; 95% CI = 0.52 to 1.58; p=0.724), employment status (OR= 0.87; 95% CI = 0.59 to 1.28; p=0.485) affected the success of TB treatment but statistically not significant.
Conclusion: Success of TB treatment is affected by age and drug side effect.
Keywords: success of treatment, tuberculosis, multi drug resistance.
Correspondence: Elisabeth Ria Widyasrini. Public Health Center, Klaten, Central Java. Email: lisabalkesmasklaten@gmail.com, mobile: +628990833108.
Journal of Epidemiology and Public Health (2017), 2(1): 45-57https://doi.org/10.26911/jepublichealth.2017.02.01.05
References
Aibana O, Bahmaha M, Kraisuk V, Rybak N, Flanigan, TP, Petrenko V (2017). Risk Factors For Poor Multidrug resistant Tuberculosis Treatment Outcomes in Kyiv Oblast, Ukraine. Bio Med Central Infectious Disease, 17 (124): 1-7.
Anderson LF, Watson JP, Tamne S, Cohen T, Mitnick T, Drobniewski F, Abubakar I (2013). Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective prospective cohort study from 2004 to 2007. European Surveillance, 18(40): 1-10.
Avong YK, Isaakidis P, Hinderaker SG, Van den Bergh R, Ali E, Obembe BO (2015). Doing No Harm? Adverse Events in A Nation-Wide Cohort of Patients with Multidrug Resistant Tuberculosis in Nigeria. Plos One, 10: 1-5.
Burhan E (2010). Tuberkulosis Multi Drug Resistance (TB-MDR). Majalah Kedokteran Indonesia, 60(12): 535-536.
Chen S, Huai P, Wang X, Zhong J, Wang X, Wang K (2013). Risk Factors for Multidrug Resistance Among Previously Treated Patients with Tuberculosis in Eastern China: a Case-Control Study. International Journal of Infectious Diseases, 17: e1116e1120.
Deshmukh R, Dhande DJ, Sachdeva KS, Sreenivas A, Kumar AMV, Satyanarayana S (2015). Patient and Provider Reported Reasons for Lost to Follow Up in MDRTB Treatment: a Qualitative Study from a Drug Resistan TB Centre in India. Plos One, 10, 1-11.
Dhingra VK, Rajpal S, Mittal A, Hanif M (2007). Outcome of Multi-Drug Resistant Tuberculosis Cases Treated Cases Treated by Individualized Regimens at a Tertiary Level Clinic. Indian Journal of Tuberculosis.15-21.
Direktorat Jendral Pengendalian Penyakit dan Penyehatan Lingkungan (2014). Pedoman Nasional Pengendalian Tuberkulosis. Kementerian Kesehatan Republik Indonesia.
Finlay A, Lancaster J, Hotlz Timothy H, Weyer K, Miranda A, Van Der Walt M (2012). Patient and Provider-Level Risk Factors Associated with Default from Tuberculosis Treatment, South Africa, 2002: a Case-Control Study. Bio Med Central Public Health, 56(12): 1-12.
Franke MF, Appleton SC, Bayona J, Arteaga F, Palacios E, Llaro K (2008). Risk Factors and Mortality Associated with Default from Multidrug Resistant Tuberculosis Treatment. National Institutes of Health Public Access, 46(12): 2-14.
Gadallah MA, Mokhtar A, Rady M, ElMoghazy E, Fawzy M, Kandil SK (2015). Prognostic Factors of Treat-ment Among Patients with Multidrug-Resistant Tuberculosis in Egypt. Journal of the Formosan Medical Association, 20: 1-7.
Gupta RD (2016). MDR-TB: An emerging burden for Bangladesh. South East Asia Journal of Public Health, 53-53.
Healy S, Dietrich S, Nyang Wa BT, Ducros P (2012).Public Health Advocacy for The Berlin Declaration on Tuberculosis in the Former Soviet Union: The View of Medecins Sans Frontieres. European Journal of Microbiology and Immunology 2(4): 282-286.
Holtz TH, Sternberg M, Kammerer S, Laserson KF, Riekstina V, Zarovska E (2006). Annals of Internal Medicine Article Time to Sputum Culture Conversion in Multidrug-Resistant Tuberculosis: Predictor and Relationship to Treatment Outcoma. Annals of Internal Medicine, 144(9): 650-659.
Ibrahim LM, Hadejia IS, Ngruku P, Dankoli R, Waziri NE, Akhimien MO (2014). Factors associated with interruption of treatment among Pulmonary Tuberculosis patients in Plateau State, Nigeria 2011. The Pan African Medical Journal, 7: 1-8.
Kondoy PPH, Rombot DV, Palandeng HMF, Pakasi TA (2014). Faktor-faktor yang berhubungan dengan kepatuhan berobat pasien Tuberkulosis Paru di Lima Puskesmas di Kota Manado. Jurnal Kedokteran Komunitas dan Tropik, 2(1): 1-8.
Kuchukhidze G, Kumar AMV, de Colombani P, Khogali M, Nanava, Blumberg HM (2014). Sort It Supplement: TB in Eastern Europe, 2012-2014. Risk factors associated with loss to followup among multidrug resistant tuberculosis patients in Gorgia.Public Health Action, 4(2): 541-546.
Milanov V, Falzon D, Zamfirova M, Varleva T, Bachiyska E, Koleva A (2015). Factors associated with treatment success and deaht in cases with multidrug-resistant tuberculosis in Bulgaria, 2009-2010. International Journal of Mycobacteriology, 4: 131-137.
Munir SM, Nawas A, Soetojo DA (2010). Pengamatan Pasien Tuberkulosis Paru dengan Multidrug Resistant (TB-MDR) di Poliklinik Paru RSUP Persahabatan. Jurnal Respirologi Indonesia, 30: 92-102.
Pant R, Pandey KR, Joshi M, Sharma S, Pandey T, Pandey S. (2009). Risk Factor Assessment of Multi Drug Resistant Tuberculosis. Journal Nepal Health Res Counc, 7(15): 89-92.
Rodriguez M, Monedero I, Caminero JA, Encarnacion M, Dominguez Y, Acosta I (2013). Successful management of multidrug resistant tuberculosis under programme conditions in the Dominican Republic. International Journal Tuberculosis Lung Disease, 17(4): 520-525.
Takarinda KC, Harries AD, Nyathi B, Ngwenya M, Mutasa-Apollo M, Sandi C (2015). Tuberculosis treatment delayes and associated factors within the Zimbabwe national tuberculosis programme. BMC Public Health, 15(29): 1-12.
Tripathi UC, Nagaraja SB, Tripathy JP, Sahu SK, Parmar M, Rade K (2015). Follow-up examinations: are multi drug resistant tuberculosis patients in Uttar Pradesh India, on track?. Public Health Action, 5(1): 59-64.
Tupasi TE, Garfin AMCG, Kurbatova EB, Mangan JM, Orillaza-Chi R, Naval LC (2016). Factors Associated with Loss to Follow up during Treatment of Muti Drug-Resistant Tuberculosis the Phillipines, 2012-2014. Emerging Infectious Diseases, 20(3): 491-502.
WHO (2015). Global Tuberculosis Report. Switzerland.
Zai S, Haroon T, Mehmood KT (2010). Socioeconomic Factors Contributing to Multidrug-Resistant Tuberculosis (MDR-TB). Journal Biomed Science and Respirology, 2(4): 279-283.
